Rezvilutamide
Jiangsu Hengrui pharmaceuticals
['prostate']
shr3680, an investigational oral ari, may be more effective than the first-generation ari bicalutamide in patients with high-volume metastatic hormone-sensitive #prostatecancer. presented at conference #asco22. #mhspc
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.